Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403039 · ClinicalTrials.gov registry record · Phase 1
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
A Phase 1 study, sponsored by Vitreous -Retina- Macula Consultants of New York.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00403039: Completed Phase 1 study, sponsored by Vitreous -Retina- Macula Consultants of New York.
NCT00403039 is a Phase 1 study that has completed, run by Vitreous -Retina- Macula Consultants of New York. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00403039, a Phase 1 study, has completed, sponsored by Vitreous -Retina- Macula Consultants of New York.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema
Interventions
- DRUG Ranibizumab (Lucentis )
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2006-11 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
What the finished NCT00403039 record still lists
NCT00403039 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab (Lucentis ) is the first listed.
NCT00403039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00403039 about?
NCT00403039 is a clinical study titled "Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema". The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema
What is the current status of trial NCT00403039?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2006-11. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00403039?
The interventions under investigation include: Ranibizumab (Lucentis ) (DRUG).
Who is sponsoring clinical trial NCT00403039?
This trial is sponsored by Vitreous -Retina- Macula Consultants of New York, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00403039's enrollment target sits among peer trials
41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia